New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:53 EDTICADiCAD shares recommended following revenue beat at Craig-Hallum
Craig-Hallum continues to recommend iCAD following the better than expected Q4 revenue beat and better than projected eBx placements. Shares are Buy rated with a $13 price target.
News For ICAD From The Last 14 Days
Check below for free stories on ICAD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
08:41 EDTICADiCAD shares recommended at Craig-Hallum
Craig-Hallum recommends buying iCAD following the announcement it acquired DermEbx and Radion. The firm views both transactions strategic and financially positive and reiterates its Buy rating and $16 price target.
07:19 EDTICADiCAD to host conference call
Subscribe for More Information
July 15, 2014
17:11 EDTICADiCAD acquires DermEbx, Radion for $12.6M in cash, stock
iCAD announced the signing of a definitive agreement to acquire DermEbx, an electronic brachytherapy services and technology provider, and Radion, a cloud-based oncology collaboration software solution. Total consideration at closing is approximately $12.6M, consisting of $3.8M in cash and 1.2M shares of iCAD common stock. The acquired companies are expected to be immediately accretive to revenues and operating cash flow. The current annual recurring revenue run-rate for DermEbx and Radion is $12M-$14M, with EBITDA margins greater than 25%. DermEbx and Radion currently service 23 locations with an active backlog of new customers. The acquisition closed July 15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use